Company · positioning
BioNTechIncumbent
Positioned in 2 collision spaces.
2Collision spaces
Nanotechnology×Disease
76.3Index
Co-developed COVID LNP-mRNA vaccine; explicitly pursuing nanoparticle-based oncology and infectious disease pipelines with the same delivery chassis.
Open collisionNanotechnology×Immunology
54.8Index
Running LNP-delivered mRNA cancer immunotherapy programs including neoantigen vaccines; the BNT111 and related oncology pipeline sits precisely at the nanoparticle-immune activation interface.
Open collision